VG

Vimal Gopinathan Nair Remadevi

Active Director Director DIN 09702692
DIN 09702692 First appointment Aug 2022 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Vimal Gopinathan Nair Remadevi

Data last updated:

Vimal Gopinathan Nair Remadevi is a Director at Ler Pharmaceuticals Private Limited (since 2022). The company operates in Chemicals.

DIN 09702692
Primary Designation Director
Industry Chemicals
First Appointment 12 Aug 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ler Pharmaceuticals Private Limited U24239KL2022PTC077322
Director12 Aug 20222022Active

Board colleagues of Vimal Gopinathan Nair Remadevi

Directorship timeline

Open interactive timeline →
Ler Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Vimal Gopinathan Nair Remadevi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vimal Gopinathan Nair Remadevi

Vimal Gopinathan Nair Remadevi currently holds 1 directorship: Ler Pharmaceuticals Private Limited (Director, since 12 Aug 2022).

Vimal Gopinathan Nair Remadevi was first appointed on 12 Aug 2022 as Director at Ler Pharmaceuticals Private Limited.

The current boards of Vimal Gopinathan Nair Remadevi's companies include Divakaran Nair Vinukumar (Ler Pharmaceuticals Private Limited), Ramachandran Rajagopal (Ler Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available